Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JNJ-26990990 is a broad-spectrum anticonvulsant drug as a second-generation followup to the marketed drug topiramate. It was designed to have the same anticonvulsant effects as topiramate, but without the side effects associated with topiramate's carbonic anhydrase inhibition. It also has potential use in the treatment of inflammatory pain, neuropathic pain, and depression. JNJ-26990990 entered phase II clinical trials in October 2007.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 133.00 | |
5 mg | In stock | $ 302.00 | |
10 mg | In stock | $ 447.00 | |
25 mg | In stock | $ 738.00 | |
50 mg | In stock | $ 987.00 | |
100 mg | In stock | $ 1,380.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 275.00 |
Description | JNJ-26990990 is a broad-spectrum anticonvulsant drug as a second-generation followup to the marketed drug topiramate. It was designed to have the same anticonvulsant effects as topiramate, but without the side effects associated with topiramate's carbonic anhydrase inhibition. It also has potential use in the treatment of inflammatory pain, neuropathic pain, and depression. JNJ-26990990 entered phase II clinical trials in October 2007. |
Molecular Weight | 242.32 |
Formula | C9H10N2O2S2 |
CAS No. | 877316-38-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 65 mg/ml (268.24 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
JNJ-26990990 877316-38-6 Others JNJ 26990990 JNJ26990990 inhibitor inhibit